HGH vs MOTS-c
FDA Approved vs Well Studied
synergistic Mechanism-based · 51% HGH helps counteract the insulin-disrupting effects of MOTS-c. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
HGH MOTS-c
Weight 22,124 Da 2,174.6 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) ~30 minutes
Chain 191 amino acids 16 amino acids
Type Single-chain polypeptide with two disulfide bridges Mitochondrial-derived peptide (MDP)
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
MOTS-c
01 Enhanced insulin sensitivity (~30% improvement)
02 Improved glucose metabolism and tolerance
03 AMPK pathway activation
04 Mitochondrial function optimization
05 Exercise performance enhancement (12-15% improvement)
06 Potential lifespan extension (6.4% median increase in mice)
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
MOTS-c
Start 5mg daily, increase to 10-15mg based on goals / Daily for metabolic support, or 3x weekly for anti-aging
Metabolic health 5-10mg Once daily
Anti-aging protocol 15mg 3x weekly
Exercise performance 10-15mg Pre-workout
Conservative start 5mg Once daily
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
MOTS-c
Generally well-tolerated in animal studies with minimal side effects
Mild injection site reactions (redness, swelling)
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Pregnancy or breastfeeding
WADA prohibited substance (banned for athletic competition)
Limited long-term human safety data
Research Evidence
HGH MOTS-c
Status FDA Approved Well Studied
References 4 studies 5 studies
Latest 2024 August 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.